Clinical Trial Update: Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluated sirolimus, tacrolimus, and methotrexate to prevent acute graft-versus-host disease in patients with hematologic cancers un…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Leukemia
• Lymphoma
• Multiple Myeloma
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms
• Plasma Cell Neoplasm

Drugs mentioned

• METHOTREXATE (METHOTREXATE)
• Sirolimus (Sirolimus)
• Tacrolimus (Tacrolimus)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 1, Phase 2 | Status: COMPLETED